Company profile



GeneCure Biotechnologies is an emerging biotechnology company focused on developing its patented gene transfer technology into effective treatments for various genetic diseases, infectious diseases, and cancers.


GeneCure's platform technology is based on a primate lentivirus, which has been shown to efficiently deliver therapeutic genes in both pre-clinical and human clinical trials with no harmful side effects.


GeneCure's lead product is a therapeutic HIV-1 vaccine for HIV-1 positive patients, HIVAX.



Commercialization strategy



GeneCure's business strategy is to enter corporate partnerships with established pharmaceutical companies interested in commercializing gene-based therapeutics. While GeneCure remains focused on conducting early research and pre-clinical studies, our commercial partners will be responsible for conducting large-scale clinical trials, manufacturing, product marketing, and distribution. This partnership model would allow the company to adapt to rapidly changing research directions while maintaining a modest cost structure.


Interested partners should contact us at: info@genecure.com



©2020 GeneCure Biotechnologies